CCDI Scientific Director at NCI
Gregory Reaman is the Scientific Director of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI) which aims to build expandable and sustainable data resources and workflows from every child and young adult with a pediatric cancer across their entire cancer trajectory from diagnosis through survivorship to enable research that ultimately provides benefit to patients through improvements in prevention, diagnosis and treatment made possible by data-focused research.
The CCDI includes a large-scale Molecular Characterization Initiative, the National Childhood Cancer Registry, the Pediatric Molecular Targets Platform and a coordinated National Rare Tumor Initiative. He previously served as Associate Director for Pediatric Oncology in the FDA’s Oncology Center of Excellence, Office of the Commissioner and Associate Director for Pediatrics in the Office of Oncologic Diseases, CDER. He is the Executive Director emeritus of the Center for Cancer and Blood Disorders at Children’s National Hospital, Washington, D.C.
He was the founding Chair of the Children’s Oncology Group and previously served as the Associate Chair for New Agent Studies and Vice Chair for Scientific Affairs of the Children’s Cancer Group. He served on the national Board of Directors of the American Cancer Society and chaired its Task Force on Cancer in Children, the Board of Directors of the American Society of Clinical Oncology and the Board of Directors of the International Society of Pediatric Oncology. He served on the Pediatric Cancer Working Group of the He was the first pediatrician member of the FDA’s Oncologic Drugs Advisory Committee and the first chair of its Pediatric Subcommittee.
He was an Associate Editor of Cancer and served on the editorial boards of Journal of Clinical Oncology, the Journal of Pediatric Hematology and Oncology and Pediatric Blood and Cancer. He is an Emeritus Professor of Pediatrics at the George Washington University School of Medicine and Health Sciences. His research interests are in the immunobiology and therapy of acute leukemia and the development of new cancer therapeutics for children. He has authored more than 375 peer-reviewed publications.
“The power of childhood cancer data speaks for itself,” he said, “and being able to aggregate, share, and broadly use these data outside of individual projects has enormous opportunities.” His hope for CCDI is that it models what’s achievable in cancer research, even outside of the pediatric population.